Multicenter Retrospective Study of 132 Patients with Unresectable Small Bowel Adenocarcinoma Treated with Chemotherapy
Open Access
- 23 May 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 17 (9) , 1163-1170
Abstract
Background. No standard chemotherapy regimen has been established for unresectable or recurrent small bowel adenocarcinoma (SBA). Methods. Clinical courses of 132 patients with unresectable or recurrent SBA who received chemotherapy at 41 institutions in Japan were reviewed retrospectively. Patients were classified into five groups according to first-line chemotherapy regimens: fluoropyrimidine monotherapy (group A), fluoropyrimidine-cisplatin (group B), fluoropyrimidine-oxaliplatin (group C), fluoropyrimidine-irinotecan (group D), and other regimens (group E). Results. The number of patients in each group was as follows: groups A, 60 patients; group B, 17 patients; group C, 22 patients; group D, 11 patients; and group E, 22 patients. Median progression-free survival (PFS) times were as follows: group A, 5.4 months; group B, 3.8 months; group C, 8.2 months; group D, 5.6 months; and group E, 3.4 months. Median overall survival (OS) times were as follows: group A, 13.9 months; group B, 12.6 months; group C, 22.2 months; group D, 9.4 months; and group D, 8.1 months. Patients in group C achieved significantly longer PFS times and substantially (but not significantly) longer OS times than patients in group A. After adjusting for clinical background characteristics, fluoropyrimidine-oxaliplatin therapy was a significant positive prognostic factor for PFS and OS times. Conclusion. The results suggest that fluoropyrimidine-oxaliplatin combination therapy is the most promising first-line chemotherapy regimen for unresectable or recurrent SBA.Keywords
This publication has 36 references indexed in Scilit:
- Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective studyBMC Cancer, 2011
- Adenocarcinoma of the small bowel: changes in the landscape?Current Opinion in Oncology, 2010
- Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO studyAnnals of Oncology, 2010
- Immunophenotype and molecular characterisation of adenocarcinoma of the small intestineBritish Journal of Cancer, 2009
- Primary Adenocarcinoma of the Small Intestine: Presentation, Prognostic Factors and Clinical OutcomeJapanese Journal of Clinical Oncology, 2008
- Chemotherapy with 5‐fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinomaCancer, 2008
- Combination Chemotherapy in Advanced Small Bowel AdenocarcinomaOncology, 2005
- Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid TumorsJournal of Clinical Oncology, 2003
- Phase III Study of Bolus Versus Infusion Fluorouracil With or Without Cisplatin in Advanced Colorectal CancerJNCI: Journal of the National Cancer Institute, 1996
- A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A mid-atlantic oncology program studyCancer, 1991